Bivalirudin vs Melanotan II
Overview
Bivalirudin is primarily a cardiovascular peptide, while Melanotan II is used for cosmetic & skin.
This page compares Bivalirudin and Melanotan II across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Melanotan II | |
|---|---|---|
| Category | Cardiovascular | Cosmetic & Skin |
| Regulatory status (US) | FDA approved | Not approved — Cat. 2 removed (Apr 2026) |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | — |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | — |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Skin tanning without UV exposure, increased libido, potential appetite suppression |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Nausea, facial flushing, darkening of moles, potential cardiovascular effects |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Melanotan II falls under Cosmetic & Skin. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Melanotan II: not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Typical dosing for Melanotan II is not catalogued.
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Melanotan II has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Melanotan II?
- Bivalirudin is primarily a cardiovascular peptide, while Melanotan II is used for cosmetic & skin. Bivalirudin is FDA-approved for one or more indications, whereas Melanotan II is not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it.
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Melanotan II used for?
- Tanning, libido.
- Can you take Bivalirudin and Melanotan II together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Melanotan II has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Melanotan II FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Melanotan II is not FDA-approved; removed from FDA's Category 2 in April 2026, which is not permission to compound it.
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Melanotan II — full monograph: mechanism, research, dosing & references